Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carmustine in BRCA1/2-associated Advanced Breast or Ovarian Cancer
DRKS00004962Phase 2Withdrawn
- Sponsor
- University of Cologne
- Start
- May 2014
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carmustine in breast cancer and ovarian cancer, sponsored by University of Cologne. Primary endpoints: Efficacy of carmustine and Safety of carmustine. Planned start May 2014; status: withdrawn.
02
Drugs
carmustine
03
Conditions
breast cancerovarian cancer
Beyond the preview
Go deeper on DRKS00004962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00004962.